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Peritonitis and exit-site infections are important complications in peritoneal dialysis (PD) patients that are occasionally caused by
opportunistic fungi inhabiting distant body sites. In this study, the oral yeast colonization of PD patients and the antifungal
susceptibility pro8le of the isolated yeasts were accessed and correlated with fungal infection episodes in the following 4 years.
Saliva yeast colonization was accessed in 21 PD patients and 27 healthy controls by growth in CHROMagar-Candida® and 18S
rRNA/ITS sequencing. PD patients presented a lower oral yeast prevalence when compared to controls, namely,Candida albicans.
Other species were also isolated, Candida glabrata and Candida carpophila. -e antifungal susceptibility pro8les of these isolates
revealed resistance to itraconazole, variable susceptibility to caspofungin, and higher MIC values of posaconazole compared to
previous reports. -e 4-year longitudinal evaluation of these patients revealed Candida parapsilosis and Candida zeylanoides as
PD-related exit-site infectious agents, but no correlation was found with oral yeast colonization.-is pilot study suggests that oral
yeast colonization may represent a limited risk for fungal infection development in PD patients. Oral yeast isolates presented
a variable antifungal susceptibility pro8le, whichmay suggest resistance to some second-line drugs, highlighting the importance of
antifungal susceptibility assessment in the clinical practice.
1. Introduction
Peritoneal dialysis (PD) is a home-based and widely used
renal replacement therapy for patients with end-stage renal
disease (ESRD). In PD patients, infectious complications,
namely, peritonitis and exit-site infections, account for
a signi8cant percentage of catheter loss, transfer to haemo-
dialysis, prolonged hospitalization, or even death, making
prevention of infection a critical step to the success of a PD
program [1]. Although a rare event, fungal peritonitis is as-
sociated with signi8cant morbidity and mortality in PD
patients [2]. Fungal exit-site infections are more frequent
than peritonitis, but more easily resolved, although they
may potentiate the development of a subsequent perito-
nitis [3]. Fungal infections are primarily caused by oppor-
tunistic fungal pathogens, such as Candida species, that take
advantage of a locally or systemically debilitated immune
system to proliferate in the human host and cause disease.
In a recent study where fungal exit-site infections of PD
patients were evaluated, the most frequently isolated
species were Candida parapsilosis (67%), followed by
Candida glabrata (10%), Candida famata (7%), and Can-
dida zeylanoides (7%) [4].
Factors that inEuence the occurrence of PD-related
infections are still not completely understood. Some au-
thors have highlighted the importance of the oral micro-
biome as a starting point for dissemination of pathogens to
distant body sites [5, 6]. Despite the association between oral
pathology and adverse outcomes of renal patients [7], so far,
existing studies have neither evaluated the oral yeast colo-
nization of PD patients nor evaluated its relation with the
development of fungal infections. -is topic is particularly
relevant when considering the opportunistic character of
Candida species, a frequent colonizer of the oral cavity [6]
and the immune impairment of ESRD patients and knowing
that chronic kidney disease itself, and PD therapy in par-
ticular, alters signi8cantly the oral milieu [8].
-erefore, in the present study, the oral yeast coloni-
zation and the oral health of PD patients were characterized
and compared with a healthy population. -e antifungal
susceptibility pro8le of yeasts isolated from the oral cavity
was also assessed. Additionally, the clinical history of fungal
infections was evaluated and related with the oral yeast
colonization of PD patients.
2. Material and Methods
Patients followed up for at least 1 month in the PD outpatient
clinic of the Nephrology Department of “Centro Hospitalar
de S. João,” over 18 years of age and with no recent history of
infection (less than 1month) were invited to participate in the
study. A convenience sample was obtained related with the
attendance of patients to the outpatient clinic during a period
of 6months. A group of 21 PD patients accepted to participate
and were included in the study. -e control group consisted
of 27 adult healthy subjects, including 10 PD family members
(in order to select individuals living in similar environment
and conditions as the patients) and 17 nonfamily members of
PD patients. -e exclusion criteria were: inability to give
informed consent, pregnancy, and severe acute illness. -e
study protocol was approved by the Ethics Committee for
Health and Institutional Review Board of “Centro Hospitalar
de S. João,” and all recruited patients and controls were asked
to give their written informed consent. -is work is consti-
tuted by a cross-sectional study, regarding the comparison of
Candida oral colonization in PD patients and controls, fol-
lowed by a longitudinal study, in which the history ofCandida
spp. infections was analysed during 4 years to establish
a comparison between the Candida species present in the oral
cavity and the Candida species responsible for subsequent
PD-related fungal infections. Regarding the longitudinal
evaluation of PD-related fungal infections, the study began
with 21 patients, and due to PD technique dropout, 20, 19, 14,
and 11 patients remained at the end of the 8rst, second, third,
and fourth follow-up year, respectively.
Patients’ clinical information was gathered including
age, gender, smoking habits, blood pressure, aetiology of
renal disease, residual renal function, PD vintage, in-
fectious complications during PD, and PD-related fungal
infection episodes and agents. Demographic information
was gathered for control population, namely, age, gender,
and smoking habits.
A noninvasive intraoral examination was performed in
both groups in order to evaluate the oral hygiene by visible
plaque index (VPI) in four sites of each tooth (mesiobuccal,
midbuccal, distobuccal, and midlingual); the percentage of
the examined sites with visible plaque ranged from 0% to
100%. Whole saliva was collected in both groups before oral
examination for microbial analysis and pH evaluation. -e
patients were instructed not to eat, drink, and perform the
normal mouth hygiene at least two hours before the pro-
cedure. Samples of nonstimulated saliva were collected in
one time point for each patient under resting conditions.-e
patients were asked to spit the whole-mouth saliva after
5min. -e volume was quanti8ed gravimetrically, and the
salivary Eow rate was determined (mL min−1). -e pH of
saliva was determined immediately after collection using pH
strips (5.0–8.0, Duotest, Germany). -e saliva was mixed
1 : 1 in Brain Heart Infusion with 20% glycerol and cry-
opreserved at −80°C until microbial analysis.
Saliva samples were unfrozen for yeast isolation and
quanti8cation. -e samples were serially diluted with 0.9%
sterile NaCl solution and plated in triplicate in a selective
and diQerential culture medium, CHROMagar-Candida.
Plates were incubated aerobically for 48 h at 37°C. Total
number of colonies was determined, and quanti8cation
results were expressed in logarithmic scale of colony forming
units per ml of saliva (Log10 CFU mL−1). Identi8cation of
Candida albicans was possible due to the speci8c colour of
the colonies. Isolates were identi8ed by 18S rDNA and
internal transcribed spacer (ITS) region DNA sequencing
approach as previously described [9]. PCR ampli8cation




GG-3′), and ITS4 (5′-TCCTCCGCTTATTGATATGC-3′)
in a -ermo-Hybaid-PX2 thermal cycler. Ampli8cation
products were visualized in a polyacrilamide gel followed by
silver-staining. Sequence analysis was performed in a genetic
analyser ABI-Prism-3100 (Applied Biosystems). Genomic
data were compared with a database that comprises a large
collection of yeast sequences of 18S rDNA and ITS regions
obtained from GenBank.
Antifungal susceptibility testing was performed by the
determination of minimum inhibitory concentration (MIC)
and according to clinical breakpoints (CBP) de8ned in the
M27-A3 and M27-S4 protocols of the Clinical and Labo-
ratory Standards Institute (CLSI) (http://clsi.org/). Due to
the loss of viability of some isolates, antifungal susceptibility
was performed in 2 isolates from the PD group and 4 out
of 10 from the controls. -e following antifungals were tested:
voriconazole (P8zer, Groton, CT), posaconazole (Schering-
Plough, Summit, NJ), Euconazole (P8zer, Groton, CT),
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amphotericin B (Bristol-Myers Squibb, New York, NY,
USA), caspofungin (Merck, Rahway, NJ, USA), anidula-
fungin (P8zer, Groton, CT, USA), and micafungin (Astellas
Pharma, Inc., Tokyo, Japan). For species whose clinical
breakpoints are not de8ned, the phenotype was character-
ized based on epidemiological cutoQ values (ECVs)
according to Pfaller and Diekema [10].
Saliva biochemical parameters were quanti8ed by an au-
tomatic analyser, Pentra C200 (Horiba ABX Diagnostics,
Switzerland). In brief, phosphate was detected by UV using
phosphomolybdate, whereas α-amylases were detected by an
enzymatic photometric test, using the substrate 4,6-ethylidene-
(G7)-p-nitrophenyl-(G1)-α-D6 maltoheptaoside (EPS-G7). In
addition, salivary IgAwas determined by immunoturbidimetry
and urea by enzymatic UV test (method “Urease–GLDH’’).
Statistical analyses were performed using IBM® SPSS®
version 23.0 (Statistical Package for Social Sciences). -e
categorical variables were described through relative fre-
quencies (%) and analysed by the chi-square independence
test or Fisher exact test when more than 1 cell had expected
counts less than 5. -e normality test was performed with
Shapiro-Wilk. When normally distributed, continuous
variables were described using mean± standard deviation
(SD) and analysed by student’s t-test, whereas when not
normally distributed, continuous variables were described
using median (min, max) and analysed by the Mann–
Whitney U test. P< 0.05 was assumed to denote a signi8cant
diQerence.
3. Results
PD patients and controls presented similar demographic
characteristics (Table 1).
-e clinical history of PD patients, such as the most
prevalent aetiologies of chronic kidney disease, and the
most relevant clinical data, such as PD vintage, residual
renal function, and blood pressure determined at the day of
sample collection, are presented in Table 2. Additionally,
this table also presents the prevalence of patients on speci8c
medication reported to be associated with altered sus-
ceptibility to fungal infections, namely, calcium channel
blockers, statins, vitamin D, and iron supplementation
[11–14].
-e study was initiated by an oral clinical evaluation and
saliva collection. At this point, the average time on PD
therapy was 15.5± 16.9 months, ranging from 1 to 72months
(Table 2).
PD patients presented a lower prevalence of yeasts in
saliva compared to the healthy controls; however, the dif-
ference did not attain statistical signi8cance (Table 3). -ree
Candida species were identi8ed, namely, C. albicans and C.
glabrata in PD patients and C. albicans and C. carpophila in
controls. -e prevalence of C. albicans was signi8cantly
lower in PD patients than in controls. One control was
colonized by two diQerent species: C. albicans and C.
glabrata. Despite the low oral yeast prevalence in PD pa-
tients, the quanti8cation of total yeast number (Log10 CFU
mL−1) in individuals colonized with yeast did not diQer
between PD patients and the control group (Table 3).
Six Candida isolates from the oral cavity were analysed
for antifungal susceptibility pro8le: 4 isolates from controls
(3 C. albicans, and 1 C. glabrata) and 2 isolates from PD
patients (1 C. albicans, and 1 C. carpophila). All the isolates
were resistant to itraconazole (MIC> 1 µg mL−1); presented
a non-wild type phenotype regarding posaconazole (NWT,
MIC> 2 µg mL−1); and were susceptible to anidulafungin
(MIC< 0.125 µg mL−1), voriconazole (MIC< 0.125 µg mL−1),
Table 1: Age and sex of peritoneal dialysis (PD) patients and
controls.
PD patients (n� 21) Controls (n� 27) P value
Age (years) 46.8± 9.7 43.2± 11.9 0.273
Sex (male, %) 42.9% 18.5% 0.066
Results are shown in prevalence (%) or mean± SD. PD, peritoneal dialysis.
Table 2: Aetiology of chronic kidney disease (CKD), time on
peritoneal dialysis, residual renal function, and blood pressure of






Other glomerular disease 33.3%
Tubulointerstitial disease 23.8%
Autosomal dominant polycystic kidney disease 14.3%
Other tubulointerstitial disease 9.5%
Unknown 23.8%
PD vintage (months) 15.5± 16.9





Calcium channel blockers 47.6%
Statins 57.1%
Vitamin D supplementation 71.4%
Iron supplementation 90.5%
Results are shown in prevalence (%). CKD, chronic kidney disease; PD,
peritoneal dialysis.
Table 3: Prevalence and quanti8cation of yeast colonizers in







Yeast prevalence 9.6% (2/21) 33.3% (9/27) 0.083
Yeasts (Log10 CFU mL−1) 2.39± 0.80 2.55± 0.82 0.803
Species prevalence
Candida albicans 4.8% (1/21) 33.3% (9/27) 0.029∗
Candida glabrata 0% 3.7% (1/27) >0.999
Candida carpophila 4.8% (1/21) 0% 0.438
Results are prevalence (%) or mean± SD. PD, peritoneal dialysis; CFU,
colony-forming units. ∗P< 0.05.
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and Euconazole (MIC< 4 µg mL−1). A similar susceptibility
pro8le was obtained for all isolates regarding amphotericin B
(MIC� 1 µg mL−1) and Eucytosine (MIC� 0.125 µg mL−1).
Candida glabrata isolated from the control group was
the only Candida isolate resistant to micafungin (MIC�
0.5 µg mL−1). A variable susceptibility to caspofungin (MIC
ranging from 0.25 to 1 µg mL−1) was observed for the
Candida isolates. -e susceptibility epidemiological cutoQs
for antifungals are still not de8ned for C. carpophila; nev-
ertheless, the susceptibility values were 0.125 µg mL−1 for
Eucytosine, 0.25 µg mL−1 for voriconazole, 0.5 µg mL−1 for
amphotericin B, 1 µg mL−1 for caspofungin and micafungin,
2 µg mL−1 for posaconazole, and 4 µg mL−1 for Euconazole,
itraconazole, and anidulafungin.
Table 4 depicts the oral factors that can play a role on
yeast growth in the oral cavity. Saliva pH and urea levels
were higher in PD patients when compared to the control
group.
Regarding PD-related fungal infections, clinical records of
this group of PD patients were analysed. In the period pre-
vious to sample collection, no peritonitis of fungal origin was
recorded, and only one exit-site infection episode was recorded
from fungal origin, namely, due to C. parapsilosis. -is pa-
tient, however, did not present yeast oral colonization at the
time of the study (approximately one year after the infection).
Moreover, concerning the longitudinal evaluation,
PD-related infections of fungal origin were recorded during
the 4 years following sample collection. During this period,
4 exit-site fungal infection episodes were recorded, 2 of
them in the same patient. -ese 2 episodes occurred with
a time diQerence of more than 5 months and were caused
by Candida parapsilosis, although in one of the episodes
bacterial agents were also isolated. Other two patients
presented infections either by Candida parapsilosis or
Candida zeylanoides. No peritonitis of fungal origin was
recorded for these patients within this time frame.
A comparison between the Candida species identi8ed in
saliva of PD patients and fungal infectious agents responsible
for the exit-site infections did not reveal the existence of
common species (Figure 1).
In addition, none of the patients that presented oral yeast
colonization developed PD-related fungal infections. Also,
no relationship was found between PD-related fungal in-
fectious agents and oral colonization of family controls.
4. Discussion
PD-related infections from fungal origin are important
complications in PD patients, and the opportunistic fungi
inhabiting distant body sites may represent a major source of
infection. According to our results, oral yeast colonization
constitutes a limited risk for fungal infections in PD patients,
due to the lack of relationship between fungal oral colonizers
and PD infectious agents. Additionally, PD patients pre-
sented a lower prevalence of oral yeasts, in particular C.
albicans, in comparison to a healthy population.
Interestingly, non-Candida albicans species were also
found to be normal colonizers of saliva, namely, C. carpo-
phila in PD patients and C. glabrata in controls. To our
knowledge, this is the 8rst study to detect the yeast C.
carpophila in human saliva. It is possible that the modi8ed
oral environment of PD patients results in a shift of yeast
prevalence compared with the healthy population resulting
in the emergence of rare yeasts, such as C. carpophila.
Several factors may contribute to the altered prevalence
of yeasts in the oral cavity of PD patients, in particular
regarding C. albicans. C. albicans is the most prevalent
fungal specie in the oral cavity, being described as more
sensitive than other Candida species to potential combined
environmental factors present in the oral cavity [15]. -us,
the lower oral C. albicans colonization of PD patients could
be justi8ed not only by a higher exposure to antifungal
therapy, recommended during an antibiotic course [16, 17],
but also by alterations of the oral environment secondary to
systemic ESRD eQects, PD therapy, and medication. Re-
garding the antifungal therapy, the protocol followed in our
department consists in the prescription of Euconazole
(100mg day−1) whenever a patient starts antibiotic therapy
after the 8rst use without success. However, since none of
our patients had an infectious episode in the month previous
to sample collection, this may not be the reason for a lower
level of Candida albicans colonization. Regarding the
medication of these patients, several molecules are reported
to be associated with altered susceptibility to fungal in-
fections and can inEuence yeast colonization in this pop-
ulation. 47.6% of the PD patients were on calcium channel
blockers therapy, described to have an inhibitory eQect on
oxidative stress response of Candida albicans [11]; 57.1%
were prescribed with statins, 3-hydroxy-3-methylglutaryl-
CoA (HMG-CoA) reductase inhibitors, used to lower pa-
tients’ cholesterol but that also aQects ergosterol levels
exhibiting antifungal properties [12]; 71.4% were supple-
mented with vitamin D known to aQect fungal growth in
Table 4: Smoking habits, oral hygiene, and saliva biochemistry of






Past (%) 58.3% 40.9% 0.331
Present (%) 16.7% 22.7% >0.999
Visual plaque index
(%) 56 (16, 100) 69 (14, 100) 0.489
Saliva biochemistry
Flow rate
(mL min−1) 0.41 (0.05, 1.06) 0.26 (0.10, 1.04) 0.432
pH 8.0 (6.5, 8.0) 6.8 (6.2, 8.0) <0.001∗
Urea (mg dL−1) 110.41± 36.64 47.85± 23.88 <0.001∗
Phosphorus
(mg dL−1) 22.76± 8.19 18.58± 16.86 0.486
IgA (mg dL−1) 143.0 (126.0,178.0)
136.5 (30.0,
167.0) 0.361
Amylase (U L−1) 309.45 (127.40,757.50)
562.6 (312.90,
571.10) 0.310
Results are prevalence (%), median (min, max) or mean± SD; PD, peri-
toneal dialysis. ∗P< 0.05.
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a dose-dependent manner [13]; and 90.5% had iron sup-
plementation, an essential element for microbial growth and
known to inEuence host susceptibility to C. albicans in-
fections [14].
In order to investigate other possible causes for the
reduced oral C. albicans colonization of PD patients, we
further evaluated speci8c oral parameters such as oral hy-
giene, smoking habits, and saliva biochemistry, given that
previous studies found relevant changes in the oral status of
chronic kidney disease patients undergoing PD [18]. In
accordance to previous studies, saliva pH and urea levels
were signi8cantly altered in PD patients in comparison with
controls [8, 19]. -e high urea levels may contribute in part
to the higher salivary pH, due to the ammonia production as
a result of urea hydrolysis [8, 19]. -is altered oral pH may
have an impact on Candida growth, given that oral Candida
isolates have been shown to be more adapted to acidic
conditions [20]. It is known that neutral to alkaline pH can
cause severe stress to C. albicans including impaired nutrient
acquisition, as a consequence of a disrupted proton gradient,
and malfunctioning of pH-sensitive proteins [21]. In addi-
tion, changes in the oral pH may be the major ecological
factor that alters the oral commensal microbiome, leading to
shifts in its natural diversity [22]. Recent advances on
bacterial–fungal interkingdom communication have shown
a negative correlation between the Candida load and the
diversity of the salivary microbiome [22]. -is suggests that,
globally, the oral microbiome of PD patients may be altered;
the impact of these changes on PD-related infections de-
serves to be further clari8ed.
Despite the limited number of isolates tested for anti-
fungal susceptibility pro8le, we veri8ed that all were resistant
to itraconazole and presented a non-wild type phenotype
regarding posaconazole. Also, the MIC values of pos-
aconazole for C. albicans and C. glabrata isolates are higher
than the previously reported values for wild-type strains
[23]. -is resistance pro8le may not be associated to the
frequent prophylactic antifungal therapy prescription dur-
ing an antibiotic course [16, 17], given that oral nystatin and
Euconazole are the common choices [1]. However, itraco-
nazole and posaconazole susceptibility pro8les in oral
Candida isolates are a matter of concern since both these
drugs are second-line agents for the treatment of oropha-
ryngeal candidiasis [24]. Also, we observed variable sus-
ceptibility pro8les of Candida isolates to caspofungin.
Taking into account that itraconazole, posaconazole, and
caspofungin are prescribed for the treatment of systemic
fungal infections [25] and that previous studies report the
existence of antifungal resistance to itraconazole and cas-
pofungin [26], we consider it relevant to determine the
susceptibility to these antifungals in all clinical isolates.
-is study presents some limitations, particularly the
limited number of patients analysed and the methodology
for yeast isolation (direct spread plate technique), which is
associated with limited sensitivity [27]. However, it is im-
portant to highlight that the percentage of Candida that we
obtained is similar to other studies that used the same
methodology [28]. On the other hand, it is important to
highlight that 10 elements of the control group were family















Figure 1: Oral Candida colonization of PD patients and healthy controls and Candida agents responsible for PD-related infections. Figure
was produced using Servier Medical Art, http://www.servier.com/Powerpoint-image-bank.
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the oral microbial colonization is strongly correlated to the
diet, oral hygiene, and familial predisposition.
In conclusion, oral yeast colonization may represent
a limited risk for fungal infections in PD patients, given
that in this pilot study there is an absence of relationship
between patients with oral yeast colonization and the
development of PD-related fungal infections; the Candida
species found in oral cavity are diQerent from the ones
identi8ed as PD-related fungal infectious agents; and also,
PD patients present a low prevalence of oral yeast colo-
nization, namely, C. albicans. Despite the low number of
oral Candida isolates, the antifungal susceptibility pro8le
revealed a possible resistance to some second-line drugs,
suggesting the need for the assessment of antifungal sus-
ceptibilities in clinical practice. Further studies are still
necessary to fully characterize the oral yeast colonization in
this population.
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